RisX Science — OncoSim
v6.1 Empirical SEER + CMS 2026Q4 + NCCN v0.4
Notes & Assumptions (v0.4 / SEER Scope)
Empirical Cohort Controls
SEER Tumor Site (T01 / T02)
State FIPS / 2025 Census Profile
SEER Combined Summary Stage (T03)
All Stages Combined
Localized
Regional
Distant
Unknown
CMS 2026Q4 NCCN Regimen Scenario
Regimen Uptake (%):
100%
Restrict to Medicare 65+ Share (SEER T02)
NCCN & Scope Provenance
US 2026 Annual Cases (T02)
-
-
State Annual Cases & Pop
-
-
Treated Cohort & Utilities
-
-
CMS 2026Q4 Base Drug Spend
-
-
SEER Combined Summary Stage Distribution (T03)
SEER Summary Stage
% of Cases
5-Year Relative Survival (%)
2026 Q4 CMS HCPCS / ASP / NADAC Drug Cost Scenarios (v0.4)
Scenario ID
NCCN Regimen
Drug
Source Dose
CMS Price ID
Base USD
Low / High USD
Real ClinicalTrials.gov NCT & 2025-2026 AACR / JCO Literature
NCT ID
Regimen / Agent
Article / Study Title
DOI / Reference
Hits
Empirical Research Baseline v0.4 — Notes, Methodology & SEER Scope Flags
Close
Loading empirical methodology notes...